Proteomics International
QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International
Under the agreement, Proteomics International has the right to use the markers to develop and commercialize a blood-based early detection test for esophageal cancer.
Proteomics International, Australian Organizations Launching A$4M Research Facility
The partners are developing a new lab that will focus on research into protein biomarkers with medical, agricultural, and environmental applications.
Proteomics International, Janssen Collaborating to Evaluate PromarkerD Kidney Disease Test
The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.
Proteomics International Investing in CPR Pharma Services
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment
Proteomics International's PromarkerD will be tested in clinical studies alongside Dimerix's investigational chronic kidney disease drug DMX-200.